Tagged with Novo Nordisk

Novo Nordisk Argentina Novo Nordisk’s largest insulin production facility outside of Denmark is in Latin America, in Brazil. Can you explain the strategic importance of this for Argentina, and how Novo Nordisk is structured here in the country? Here in Argentina Novo Nordisk has an affiliate focused on commercial activities, clinical research and…

Novo Nordisk Hungary We understand that you have been with Novo Nordisk for quite a while already. In the past decade, you also did not sit still in terms of location, working in different international contexts. Can you give our readers some background on the market environment when you first started heading the…

Novo Nordisk (Serbia) Novo Nordisk has a long history in Serbia compared to many of the other multinational companies present in the country today. The separate entity Novo Nordisk d.o.o was founded in 2006, but you have been present in the market for over 20 years. Given this history, how would you describe…

Novo Nordisk Pharma Sp. z.o.o Apart from Poland being a 40 million population market, with double digit growth, Mr. Kuczynski of Pierre Fabre was telling us that the main opportunity of the Polish market lies in the many unmet, local medical needs. What are the main specificities of the Polish market in your view and…

Novo Nordisk UK This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does the European region and the UK represent for the company? The European markets are growing in the order of 3-5%…

Novo Nordisk Pharmaceuticals (Philippines) Given that Asia is leading growth in the global pharmaceutical market, how is Novo Nordisk represented in the Asia-Pacific region and what is the importance of the Philippines within the company’s strategy for Asia? The Philippines is part of what we call BAOS – Business Area Oceana, which includes Australia…

Novo Nordisk Taiwan Novo Nordisk is one of the few pharmaceutical multinationals focused in one key therapeutic area. Perhaps you could start by telling our readers about how diabetes has evolved in Taiwan over the last few years, and what the situation is like today. The prevalence of diabetes is increasing as in…

Novo Nordisk Europe Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries such as Mexico and Brazil. Indeed, Novo Nordisk’s biggest insulin production facility outside of Denmark is in Brazil. Given these…